Vital Signs with Jacob Effron and Nikhil Krishnan
Ep 52: knownwell CMO Dr. Angela Fitch on The Future of GLP-1s and New Approaches to Obesity Medicine
Nov 14, 2024
Dr. Angela Fitch, Founder and CMO of knownwell, shares her expertise on obesity medicine, emphasizing the need for innovative care. She discusses the transformative potential of GLP-1 medications, highlighting their impact beyond obesity treatment to conditions like Alzheimer’s. The conversation also addresses challenges in insurance coverage and the importance of continuous and integrated care. Dr. Fitch advocates for recognizing obesity as a serious medical condition and stresses the necessity of creating a supportive environment for effective treatment.
38:53
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Dr. Angela Fitch highlights the transformative potential of GLP-1 medications in reshaping obesity treatment but warns of accessibility challenges.
- The establishment of knownwell aims to provide inclusive and integrated care for obesity by addressing systemic stigma and fragmentation in healthcare.
Deep dives
Current Standards of Care in Obesity Medicine
The evolving landscape of obesity medicine is marked by the push to develop comprehensive standards of care, which have been notably absent. Dr. Angela Fitch emphasizes that the increasing availability of effective medications, particularly GLP-1 agonists, is reshaping perceptions and practices in the treatment of obesity. However, the stigma surrounding obesity continues to hinder patients from seeking proper care, often leading them to alternative, less coordinated approaches. There is a critical need for unified guidelines and a collaborative care model that facilitates better access and understanding of obesity as a complex disease.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
